Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection

Anaerobe

Volumn 21, Issue , 2013, Pages 28-33

  Bolla, Patricia A ^a,b   Carasi, Paula ^a   Bolla, María de los Angeles ^c   De Antoni, Graciela L ^a,b   Serradell, María de los Angeles ^a  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c Hospital Interzonal General de Agudos Dr Rodolfo Rossi   (Argentina)

Author keywords

C. difficile; Hamsters; Kefir

Indexed keywords

CLINDAMYCIN; CLOSTRIDIUM TOXIN; KEFIR; PLACEBO; PROBIOTIC AGENT; BACTERIAL TOXIN; LACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; FEMALE; KLUYVEROMYCES MARXIANUS; LACTIC ACID BACTERIUM; LACTOBACILLUS KEFIR; LACTOBACILLUS PLANTARUM; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SYRIAN HAMSTER; ANIMAL; DAIRY PRODUCT; DIARRHEA; DISEASE MODEL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; KLUYVEROMYCES; LACTOBACILLUS; MESOCRICETUS; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; CRICETINAE; KLUYVEROMYCES MARXIANUS; LACTOBACILLUS KEFIRI; LACTOBACILLUS PLANTARUM; POSIBACTERIA; SACCHAROMYCES CEREVISIAE;

ADMINISTRATION, ORAL; ANIMALS; BACTERIAL TOXINS; CECUM; CLOSTRIDIUM DIFFICILE; CRICETINAE; CULTURED MILK PRODUCTS; DIARRHEA; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; KLUYVEROMYCES; LACTIC ACID; LACTOBACILLUS; MESOCRICETUS; SACCHAROMYCES CEREVISIAE;

EID: 84877107619     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2013.03.010     Document Type: Article

References (37)

1. Farnworth E. Kefir - a complex probiotic. Food Science and Technology Bulletin: Functional Foods 2005, 2:1-17.
2. Servin A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiology Reviews 2004 Oct, 28(4):405-440. Review.
3. Corthésy B., Gaskins H.R., Mercenier A. Cross-talk between probiotic bacteria and the host immune system. Journal of Nutrition 2007 Mar, 137(3 Suppl. 2):781S-790S. Review.
4. Sun X., Wang H., Zhang Y., Chen K., Davis B., Feng H. Mouse relapse model of Clostridium difficile infection. Infection and Immunity 2011, 79:2856-2864.
5. Tam Dang T.H., Fagan R.P., Fairweather N.F., Tate E.W. Novel inhibitors of surface layer processing in Clostridium difficile. Bioorganic & Medicinal Chemistry 2011, 20:614-621.
6. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therapeutic Advances in Gastroenterology 2011, 4:185-197.
7. Trejo F.M., Minnaard J., Pérez P.F., De Antoni G.L. Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants. Anaerobe 2006, 12:186-193.
8. Trejo F.M., Pérez P.F., De Antoni G.L. Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile invitro. Antonie Van Leeuwenhoek 2010, 98:19-29.
9. Banerjee P., Merkel G.J., Bhunia A.K. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathogens 2009, 1:8.
10. Carasi P., Trejo F.M., Pérez P.F., De Antoni G.L., Serradell M.D. Surface proteins from Lactobacillus kefir antagonize invitro cytotoxic effect of Clostridium difficile toxins. Anaerobe 2012, 18:135-142.
11. Castagliuolo I., LaMont J.T., Nikulasson S.T., Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and Immunity 1996, 64:5225-5232.
12. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infection and Immunity 1999, 67:302-307.
13. Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane C.J., Castagliuolo I., et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993, 104:1108-1115.
14. Tung J.M., Dolovich L.R., Lee C.H. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Canadian Journal of Gastroenterology 2009, 23:817-821.
15. Venuto C., Butler M., Ashley E., Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy 2010, 30:1266-1278.
16. Lowe B.R., Fox J.G., Bartlett J.G. Clostridium difficile-associated cecitis in guinea pigs exposed to penicillin. American Journal of Veterinary Research 1980, 41:1277-1279.
17. Carman R.J., Borriello S.P. Infectious nature of Clostridium spiroforme-mediated rabbit enterotoxaemia. Veterinary Microbiology 1984, 9:497-502.
18. Czuprynski C.J., Johnson W.J., Balish E., Wilkins T. Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infection and Immunity 1983, 39:1368-1376.
19. Chen X., Katchar K., Goldsmith J.D., Nanthakumar N., Cheknis A., Gerding D.N., et al. Amouse model of Clostridium difficile-associated disease. Gastroenterology 2008, 135:1984-1992.
20. Larson H.E., Price A.B., Honour P., Borriello S.P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978, 20:1063-1066.
21. Borriello S.P., Barclay F.E. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. Journal of Medical Microbiology 1985, 19:339-350.
22. Trejo F.M. Interacción entre Clostridium difficile, lactobacilos y bifidobacterias 2009, Ph.D Thesis, Facultad de Ciencias Exactas, Universidad Nacional de La Plata.
23. Buckley A.M., Spencer J., Candlish D., Irvine J.J., Douce G.R. Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291. Journal of Medical Microbiology 2011, 60:1174-1180.
24. Garrote G., Abraham A., De Antoni G. Chemical and microbiological characterisation of kefir grains. Journal of Dairy Research 2001, 68:639-652.
25. Delfederico L., Hollmann A., Martínez M., Iglesias N.G., De Antoni G., Semorile L. Molecular identification and typing of lactobacilli isolated from kefir grains. Journal of Dairy Research 2006, 73:20-27.
26. Hamet F. Polisacáridos de bacterias lácticas de fermentos artesanales para el desarrollo de alimentos funcionales 2012, Ph.D Thesis, Facultad de Ciencias Exactas, Universidad Nacional de La Plata.
27. Bolla P.A., Serradell M. de L., de Urraza P.J., De Antoni G.L. Effect of freeze-drying on viability and invitro probiotic properties of a mixture of lactic acid bacteria and yeasts isolated from kefir. Journal of Dairy Research 2011, 78:15-22.
28. Bolla P.A., Carasi P., Serradell M. de.L.A., De Antoni G.L. Kefir-isolated Lactococcus lactis subsp. lactis inhibits the cytotoxic effect of Clostridium difficile in vitro. Journal of Dairy Research 2013, 80:96-102.
29. Abraham A., De Antoni G., Añón M. Effect of calcium on the cryopreservation of L. bulgaricus in different freezing media. Cryobiology 1990, 27:186-193.
30. Minnaard J., Humen M., Pérez P.F. Effect of Bacillus cereus exocellular factors on human intestinal epithelial cells. Journal of Food Protection 2001, 64:1535-1541.
31. Verna E.C., Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend?. Therapeutic Advances in Gastroenterology 2010, 3:307-319.
32. McFarland L.V. Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. American Journal of Gastroenterology 2006, 101:812-822.
33. McFarland L.V. Evidence-based review of probiotics for antibiotic-associated diarrhoea and Clostridium difficile infections. Anaerobe 2009, 15:274-280.
34. Hickson M., D'Souza A.L., Nuthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. British Medical Journal 2007, 335:80.
35. Razaq N., Sambol S., Nagaro K., Zukowski W., Cheknis A., Johnson S., et al. Infection of hamsters with historical and epidemic BI types of Clostridium difficile. Journal of Infectious Diseases 2007, 196:1813-1819.
36. Ochsner U.A., Bell S.J., O'Leary A.L., Hoang T., Stone K.C. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and invivo efficacy in a hamster gastrointestinal infection model. Journal of Antimicrobial Chemotherapy 2009, 63:964-971.
37. Keel M.C., Songer J.G. The comparative pathology of Clostridium difficile-associated disease. Veterinary Pathology 2006, 43:225-240.